NLMSF Logo
(303) 808-3437Donate Now
NLMSF Logo
(303) 808-3437Donate Now
Patient Guide

What to Know About Uterine Leiomyosarcoma

Essential information for patients and caregivers about uterine LMS — treatment, follow-up, recurrence management, emerging therapies, and critical safety warnings.

Overview

Uterine Leiomyosarcoma (uLMS)

A rare and aggressive uterine malignancy

Uterine sarcomas are rare and heterogeneous malignant mesenchymal tumors, representing only 1% to 3% of gynecological cancers and 3% to 7% of uterine malignancies, with an annual global incidence of 0.5 to 3.3 cases per 100,000 women.

These tumors are the most lethal among uterine malignancies, exhibiting a 5-year overall survival rate of 25% to 70%, depending on histologic subtype and stage. Uterine leiomyosarcoma is the predominant subtype, accounting for 60%–70% of cases.

2025 Science Direct Update

Understanding uLMS: Expert Video

Primary Treatment

Treatment decisions for uterine leiomyosarcoma are complex and often based on limited and controversial evidence. For resectable disease, early and complete resection is the cornerstone of management, as surgery is currently the only curative option for uterine leiomyosarcoma.

In cases of unresectable, metastatic, or recurrent disease, a multimodal treatment strategy including surgery, chemotherapy, and radiotherapy (RT) is recommended. Centralized management in referral centers is advised.

Follow-Up

Due to the aggressive nature of uterine leiomyosarcoma and the high risk of recurrence, diligent clinical and radiological follow-up is essential. Patients must be educated on the symptoms of recurrence and the need for timely medical consultation.

Clinical follow-up, including a comprehensive history and physical examination, is recommended every 3 to 4 months during the first 2 to 3 years, then every 6 to 12 months thereafter.

Radiological monitoring with contrast-enhanced CT of the chest, abdomen, and pelvis is recommended at regular intervals.

Treatment of Recurrent Disease

Recurrent uterine leiomyosarcoma often presents as abdominal/pelvic disease or isolated lung metastases. Managing recurrent uterine leiomyosarcoma requires a tailored, patient-centered approach, similar to that used in the advanced/metastatic setting.

This multidisciplinary approach integrates systemic chemotherapy and/or loco-regional treatment based on the recurrence site, local resectability, prior therapies, and disease-free interval.

Novel Therapeutic Agents & Future Perspectives

Advances in multi-omics and molecular insights offer promising avenues for personalized treatment in uterine leiomyosarcoma. Potential approaches under investigation include:

  • Anti-angiogenic agents
  • Immune checkpoint inhibitors
  • Agents targeting HER-2 (human epidermal growth factor receptor 2)
  • PARP inhibitors
  • Novel combination regimens

However, designing prospective clinical trials for uterine leiomyosarcoma faces challenges due to its rarity.

National Cancer Institute Resources

NCI — Leiomyosarcoma

Rare soft tissue tumor overview from the National Cancer Institute

View Resource

Staging & Treatment

NCI uterine sarcoma treatment PDQ for patients

View Resource

FIGO Surgical Staging

MSD Manual — FIGO staging of uterine sarcoma

View Resource

Laparoscopic Power Morcellators — Safety Warning

Important Patient Alert

Read carefully and discuss with your provider

Read more and make sure you discuss thoroughly with your provider if this procedure is introduced and suggested to you. This information is posted as an important warning alert.

FDA Update (May 26, 2023)

The FDA issued final guidance: Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures. This guidance provides recommendations to help manufacturers comply with special controls related to non-clinical performance data for gynecologic and general use laparoscopic power morcellation containment systems.

Laparoscopic power morcellators are Class II medical devices used during laparoscopic (minimally invasive) surgeries to cut tissue into smaller pieces so the tissue can be removed through a small incision site (typically 2 cm or less). These devices are commonly used in hysterectomy and myomectomy procedures.

FDA: Laparoscopic Power Morcellators

Key Warnings from Medical Organizations

ACOG — Uterine Morcellation for Presumed Leiomyomas

Leiomyosarcoma cannot be reliably diagnosed preoperatively; thus, there is a risk that a woman with a presumed leiomyoma may have a malignancy that may be spread through morcellation, leading to a potentially worsened prognosis.

No. 371 — Morcellation During Gynaecologic Surgery

Women should be counselled that in the case of unexpected uterine (sarcoma, endometrial), cervical, and/or tubo-ovarian cancer, the use of a morcellator is associated with increased risk of tumour dissemination.

Uterine LMS Research HubABC's of New Diagnosis